Merck Animal Health Announces Availability of Sequivity IAV-S NA for Swine | MRK Message Board Posts


Merck and Co., Inc.

  MRK website

MRK   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  737 of 746  at  11/4/2023 1:04:57 PM  by

jerrykrause


Merck Animal Health Announces Availability of Sequivity IAV-S NA for Swine

 Pharma & Healthcare Monitor Worldwide
 

Merck Animal Health Announces Availability of Sequivity IAV-S NA for Swine

 

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that SEQUIVITY IAV-S NA (Swine Influenza Vaccine, N1 and N2, RNA Particle) vaccine is commercially available as part of its swine product portfolio. The

company received license approval for the vaccine from the U.S. Department of Agriculture (USDA) in 2022.

The SEQUIVITY IAV-S NA vaccine is the first commercial vaccine that uses only the influenza neuraminidase (NA) surface antigen to vaccinate pigs against influenza strains H1N1, H1N2 and H3N2. The NA RNA particles in the vaccine are produced using the innovative SEQUIVITY platform technology from Merck Animal Health that previously has been used to

target existing and emerging swine pathogens.

"Merck Animal Health is excited to bring this important innovation to our customers as it demonstrates our mission to bring forward solutions to solve swine disease challenges and improve animal health," said Channing Sebo-Decker, D.V.M., swine technical services veterinarian, Merck Animal Health. "The SEQUIVITY IAV-S NA vaccine represents a novel

technological advancement and creates a new tool for influenza control programs."

The frozen vaccine is mixed with Microsol Diluvac Forte adjuvant at point of use. Pigs can be vaccinated as early as three days of age followed by a booster three weeks later.

The duration of the immunity against the H1N1 subtype is at least 12 weeks post-booster dose. The licensing trials demonstrated that the vaccine was safe and significantly reduced IAV-associated lung lesions and nasal shedding against five challenge strains from the H1N1, H1N2 and H3N2

subtypes.

SEQUIVITY IAV-S NA vaccine is available in 50-dose and 250-dose presentations. To learn more about our portfolio of swine health products and vaccines, visit www.DrivenByPrevention.com . SEQUIVITY IAV-S NA PRODUCT LABEL: https://merckusa.cvpservice.com/product/view/1047585

 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...